Paromomycin is superior to metronidazole in Dientamoeba fragilis treatment

Publication date: Available online 11 November 2019Source: International Journal for Parasitology: Drugs and Drug ResistanceAuthor(s): Ander Burgaña Agoües, Rosa Abellana, Stanislav Zlatanov Yordanov, Rabee Kazan, A. Mauricio Pérez Ortiz, Cristina Castillo Ramos, Christian Garavito Hernández, Miriam Molina Rivero, Alessandra Queiroga Gonçalves, Emma Padilla, Josefa Pérez, Roger García Puig, Tomas M. Perez-PorcunaABSTRACTDientamoeba fragilis is a trichomonad parasite of the human intestine that is found worldwide. However, the biological cycle and transmission of this parasite have yet to be elucidated. Although its pathogenic capacity has been questioned, there is increasing evidence that clinical manifestations vary greatly. Different therapeutic options with antiparasitic drugs are currently available; however, very few studies have compared the effectiveness of these drugs. In the present longitudinal study, we evaluate 13,983 copro-parasitological studies using light microscopy of stools, during 2013-2015, in Terrassa, Barcelona (Spain). A total of 1150 (8.2%) presented D. fragilis. Of these, 739 episodes were finally analyzed: those that involved a follow-up parasitology test up to 3 months later, corresponding to 586 patients with gastrointestinal symptoms (53% under 15 years of age). Coinfection by Blastocystis hominis was present in 33.6% of the subjects. Our aim was to compare therapeutic responses to different antiparasitic drugs and the factors associated wi...
Source: International Journal for Parasitology: Drugs and Drug Resistance - Category: Parasitology Source Type: research